Skip to content

Proximal Ventures raises $27.5 million to automate drug-development services

Share
Proximal Ventures raises $27.5 million to automate drug-development services

Listen to this article

Read by Anchor

Amid one of the toughest fundraising environments that new fund managers have faced in years, Saheer Rauf closed his first single-manager investment fund, Proximal Ventures, with $27.5 million, betting on automating the tools, infrastructure and services that support drug-development pathways through artificial intelligence. The move comes as institutional capital is moving cautiously toward emerging funds, while Rauf chose to direct this financing toward cracking one of the most complex and costly medical sectors.

Large pharmaceutical companies have historically outsourced extended phases of drug development, from manufacturing thousands of molecular compounds and scaling production to commercial volumes, to auditing clinical trial data. For decades the industry has relied on the commercial belief that pharma firms are not good buyers of pure software, but remain excellent buyers of specialized contract services that consume budgets in the billions.

Rauf believes artificial intelligence can automate a wide portion of this operational effort, opening the door for startups to capture a tangible share of global pharma spending by offering the same services at lower cost and much shorter timelines. The fund’s founder measures this path against sectors that depend on services such as law and finance, where AI tools have delivered their highest returns by dismantling repetitive work chains.Automating contract services represents the operational gap for seizing billions of drug budgets instead of trying to sell isolated software.

The fund plans to invest in pre-seed and seed-stage companies, writing checks ranging from $500,000 to $1.5 million. Proximal Ventures has already invested in seven startups, including Chronical Bio, co-founded by former OpenAI executive Fidgee Simo, which relies on AI algorithms to analyze biological and medical data for a more precise understanding of chronic diseases and the identification of promising therapies.

The fund’s financing bet stems from the founder’s prior field experience selling solutions to medical institutions; market experience shows that the toughest challenge for any company selling to the life-science sector is moving the initial “budget-wheel” and earning client trust. Rauf previously served as a senior manager at Signal Fire for two years, led business development at Iterative Health, which recruits participants for clinical trials, and oversaw partnerships at Flatiron Health, an oncology-data specialist acquired by Roche for $1.9 billion in 2018.Kick-starting commercial traction in life sciences requires a strong network and penetration of regulatory bottlenecks before building models.

This professional record has boosted limited partners’ confidence in Rauf’s ability to spot promising companies and help them close commercial contracts, attracting prominent backers for the fund including Signal Fire, Klein Perkins, and Birtlesman Healthcare, as well as Nan Li and Zaven Dar of Dimension Capital. Emily Abernathy, co-founder of Highlander Health and former deputy commissioner of the U.S. Food and Drug Administration, who previously worked with Rauf as a senior medical officer at Flatiron Health, also participated, confirming that his ability to identify industry bottlenecks and understand health-care market needs gives him an edge in early-stage rounds alongside the largest funds.

This shift in biotech financing has direct implications for health institutions and research centers in the Gulf, Egypt and the Arab Levant. As research clusters accelerate, clinical-trial localization and genome-sequencing efforts expand, reliance on automated laboratory and analytical services reduces the hefty bills that regional hospitals and health authorities currently pay to Western service companies. It also gives local biotech teams a chance to move beyond selling software licences to hospitals and instead provide fast, automated testing services that meet clinical standards and lower national research costs.

Proximal Ventures’ experience shows that real competition in medical AI is moving toward field efficiency that cuts research cost and time, not merely theoretical flash. The decisive benchmark for these investments will be startups’ ability to survive in labs and meet strict regulatory standards, turning early funding into tangible clinical solutions.

Don't miss the next story

Subscribe for updates